Archive — US — techcrunch
Early cancer detection startup Craif raises $22M
Craif, a cancer detection startup from Japan, has raised $22M in Series C funding to expand its AI-powered urine-based detection technology in the U.S. Following a $57M total funding, it aims to leverage microRNA for early cancer detection, addressing challenges in traditional methods. Founded in 2018, Craif's non-invasive testing is based on significant personal and scientific motivations, with plans for broader applications.
Key points
- Craif raised $22 million in Series C funding led by X&KSK and Unreasonable Group.
- Total funding to date is $57 million, with a valuation just under $100 million.
- The startup uses microRNA for early cancer detection, focusing on non-invasive urine tests.
- Onose's personal experience with cancer (family history) drove the company's mission.
- Traditional methods are invasive and less accessible, which Craif aims to remedy.
- Craif’s first product, miSignal, detects multiple types of cancer and is already generating revenue in Japan with $5 million in 2024, aiming for $15 million this year.
- Plans to expand its technology to non-cancerous diseases like dementia by 2025 and seek FDA approval by 2027.
Why it matters
- The global cancer incidence is projected to rise significantly, indicating a pressing need for innovative detection methods.
- The use of microRNA in cancer detection aligns with a broader trend in precision medicine and personalized healthcare.
- The startup ecosystem for cancer detection is growing, as seen with competitors like Grail and Freenome, highlighting industry interest in non-invasive diagnostics.
Craif's advancements in early cancer detection using microRNA and urine-based tests represent a significant step towards accessible healthcare, leveraging personal motivation and cutting-edge science to address a critical global health issue.